Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites

Bioanalysis

Volumn 4, Issue 5, 2012, Pages 501-510

  Ma, Shuguang ^a   Chowdhury, Swapan K ^b  

^a GENENTECH INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DICLOFENAC; DRUG METABOLITE; GLUTATHIONE; MENTHOFURAN; PARACETAMOL; PULEGONE; TICLOPIDINE;

ACCURACY; ANALYZER; DRUG DETERMINATION; DRUG STRUCTURE; FILTER; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NOISE REDUCTION; NONHUMAN; PROCESS DEVELOPMENT; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DRUG EVALUATION, PRECLINICAL; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS;

EID: 84858391360     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.5     Document Type: Review

References (35)

1. Park BK, Boobis A, Clarke S et al. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10(4), 292-306 (2011). nExcellent review on approaches for handling metabolic activation of drug candidates in drug development.
2. Nakayama S, Atsumi R, Takakusa H et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37(9), 1970-1977 (2009). nDemonstration of a potential correlation of the extent of covalent binding and daily dose with observed clinical toxicity.
3. Baillie TA. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21(1), 129-137 (2008
4. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17(1), 3-16 (2004). nOverview of strategies for minimizing the potential for metabolic activation in drug discovery and development.
5. Ma S, Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179(1), 25-37 (2009). nExcellent review on the analtytical techniques for the screening of reactive drug metabolites by LC-MS/MS.
6. Ma S, Subramanian R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 41(9), 1121-1139 (2006
7. Castro-Perez J, Plumb R, Liang L, Yang E. A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun. Mass Spectrom. 19(6), 798-804 (2005
8. Yan Z, Caldwell GW, Maher N. Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. Anal. Chem. 80(16), 6410-6422 (2008
9. Yan Z, Caldwell GW. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal. Chem. 76(23), 6835-6847 (2004
10. Leblanc A, Shiao TC, Roy R, Sleno L. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. Rapid Commun. Mass Spectrom. 24(9), 1241-1250 (2010
11. Dieckhaus CM, Fernandez-Metzler CL, King R, Krolikowski PH, Baillie TA. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol. 18(4), 630-638 (2005
12. Zhu X, Kalyanaraman N, Subramanian R. Enhanced screening of glutathione-trapped reactive metabolites by in-source collision-induced dissociation and extraction of product ion using UHPLC-high resolution mass ppectrometry. Anal. Chem. 83(24), 9516-9523 (2011
13. Andrews GL, Simons BL, Young JB, Hawkridge AM, Muddiman DC. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal. Chem. 83(13), 5442-5446 (2011
14. Junot C, Madalinski G, Tabet JC, Ezan E. Fourier transform mass spectrometry for metabolome analysis. Analyst 135(9), 2203-2219 (2010
15. Makarov A, Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J. Chromatogr. A 1217(25), 3938-3945 (2010
16. Scigelova M, Makarov A. Advances in bioanalytical LC-MS using the Orbitrap mass analyzer. Bioanalysis 1(4), 741-754 (2009
17. Zhang H, Zhang D, Ray K, Zhu M. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J. Mass Spectrom. 44(7), 999-1016 (2009). nComprehensive review on mass defect filter and its application to metabolite identification.
18. Zhang H, Zhang D, Ray K. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J. Mass Spectrom. 38(10), 1110-1112 (2003
19. Zhang H, Yang Y. An algorithm for thorough background subtraction from high-resolution LC-MS data: Application for detection of glutathione-trapped reactive metabolites. J. Mass Spectrom. 43(9), 1181-1190 (2008
20. Zhu P, Ding W, Tong W, Ghosal A, Alton K, Chowdhury S. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices. Rapid Commun. Mass Spectrom. 23(11), 1563-1572 (2009). nDetailed description of the background subtraction and noise reduction algorithm.
21. Zhu P, Tong W, Alton K, Chowdhury S. An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data. Anal. Chem. 81(14), 5910-5917 (2009). nDetailed description of the isotope pattern-filtering algorithm.
22. Zhu M, Ma L, Zhang H, Humphreys WG. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal. Chem. 79(21), 8333-8341 (2007
23. Ruan Q, Zhu M. Investigation of bioactivation of ticlopidine using linear ion trap/Orbitrap mass spectrometry and an improved mass defect filtering technique. Chem. Res. Toxicol. 23(5), 909-917 (2010
24. Barbara JE, Castro-Perez JM. High-resolution chromatography/time-of- flight MSE with in silico data mining is an information-rich approach to reactive metabolite screening. Rapid Commun. Mass Spectrom. 25(20), 3029-3040 (2011
25. Ma S, Yuan Y, Lu X et al. High-throughput screening of drug reactive metabolites using accurate-mass-based background subtraction and noise reduction algorithm. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics. Salt Lake City, UT, USA, 23-27 May 2010.
26. Ma L, Wen B, Ruan Q, Zhu M. Rapid screening of glutathione-trapped reactive metabolites by linear ion trap mass spectrometry with isotope pattern-dependent scanning and postacquisition data mining. Chem. Res. Toxicol. 21(7), 1477-1483 (2008
27. Rousu T, Pelkonen O, Tolonen A. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 23(6), 843-855 (2009
28. Lim HK, Chen J, Cook K, Sensenhauser C, Silva J, Evans DC. A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 22(8), 1295-1311 (2008
29. Ruijken MMA. MsXelerator RM: A software platform for reactive metabolite detection using low and high resolution mass spectrometry data. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics. Salt Lake City, UT, USA, 23-27 May 2010.
30. Gan J, Harper TW, Hsueh MM, Qu Q, Humphreys WG. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18(5), 896-903 (2005
31. Gan J, Ruan Q, He B, Zhu M, Shyu WC, Humphreys WG. In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol. 22(4), 690-698 (2009
32. Soglia JR, Contillo LG, Kalgutkar AS et al. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem. Res. Toxicol. 19(3), 480-490 (2006
33. Hollenberg PF, Kent UM, Bumpus NN. Mechanism-based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol. 21(1), 189-205 (2008
34. Humphreys WG. Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design. Chem. Biol. Interact. 192(1-2), 56-59 (2011
35. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 37(12), 2383-2392 (2009).